EP4719454A2 - Agents de substitution wnt et méthodes de régénération de glande lacrymale - Google Patents

Agents de substitution wnt et méthodes de régénération de glande lacrymale

Info

Publication number
EP4719454A2
EP4719454A2 EP24816301.6A EP24816301A EP4719454A2 EP 4719454 A2 EP4719454 A2 EP 4719454A2 EP 24816301 A EP24816301 A EP 24816301A EP 4719454 A2 EP4719454 A2 EP 4719454A2
Authority
EP
European Patent Office
Prior art keywords
wnt signaling
seq
engineered
signaling modulator
wnt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24816301.6A
Other languages
German (de)
English (en)
Inventor
Yang Li
Huy Tuan Nguyen
Yorick POST
Wen-Chen Yeh
Thomas Steven LOPEZ
Randall J. Brezski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Surrozen Operating Inc
Original Assignee
Surrozen Operating Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Surrozen Operating Inc filed Critical Surrozen Operating Inc
Publication of EP4719454A2 publication Critical patent/EP4719454A2/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La divulgation concerne des procédés et des compositions permettant de régénérer des cellules de glandes lacrymales pour le traitement de troubles de sécheresse oculaire. En particulier, la présente divulgation concerne des méthodes et des compositions permettant de moduler la signalisation WNT par administration d'un agoniste de signalisation WNT modifié chez un sujet pour moduler la régénération de cellules acineuses productrices de larmes pour traiter des maladies de sécheresse oculaire de type déficient aqueux.
EP24816301.6A 2023-05-29 2024-05-28 Agents de substitution wnt et méthodes de régénération de glande lacrymale Pending EP4719454A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363469496P 2023-05-29 2023-05-29
PCT/US2024/031308 WO2024249444A2 (fr) 2023-05-29 2024-05-28 Agents de substitution wnt et méthodes de régénération de glande lacrymale

Publications (1)

Publication Number Publication Date
EP4719454A2 true EP4719454A2 (fr) 2026-04-08

Family

ID=93658811

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24816301.6A Pending EP4719454A2 (fr) 2023-05-29 2024-05-28 Agents de substitution wnt et méthodes de régénération de glande lacrymale

Country Status (4)

Country Link
EP (1) EP4719454A2 (fr)
CN (1) CN121568704A (fr)
AU (1) AU2024279826A1 (fr)
WO (1) WO2024249444A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11773171B2 (en) 2017-12-19 2023-10-03 Surrozen Operating, Inc. WNT surrogate molecules and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015314771B2 (en) * 2014-09-12 2021-04-01 The Board Of Trustees Of The Leland Stanford Junior University Wnt signaling agonist molecules
US11773171B2 (en) * 2017-12-19 2023-10-03 Surrozen Operating, Inc. WNT surrogate molecules and uses thereof
US20210292422A1 (en) * 2018-07-05 2021-09-23 Surrozen, Inc. Multi-specific wnt surrogate molecules and uses thereof
CA3144499A1 (fr) * 2019-07-02 2021-01-07 Surrozen Operating, Inc. Anticorps anti-fzd monospecifiques et methodes d'utilisation
AU2022413699A1 (en) * 2021-12-17 2024-07-04 Surrozen Operating, Inc. Wnt-surrogate agents and methods for lacrimal gland regeneration

Also Published As

Publication number Publication date
WO2024249444A3 (fr) 2025-03-27
WO2024249444A2 (fr) 2024-12-05
AU2024279826A1 (en) 2026-01-08
CN121568704A (zh) 2026-02-24

Similar Documents

Publication Publication Date Title
US20250313616A1 (en) Modulation of wnt signalling in ocular disorders
US20250051459A1 (en) Wnt-surrogate agents and methods for lacrimal gland regeneration
JP2024001292A (ja) 多特異性Ｗｎｔ代替分子及びその使用
US20220195053A1 (en) Modulation of wnt signaling in gastrointestinal disorders
US20220175884A1 (en) Modulation of wnt signaling in auditory disorders
US20240391991A1 (en) Modulation of wnt signalling in pulmonary disorders
WO2023250291A2 (fr) Modulation de la signalisation wnt dans des troubles cornéens
JP7813894B2 (ja) Ｗｎｔレセプター特異的化合物及びそれに関連する方法
EP4719454A2 (fr) Agents de substitution wnt et méthodes de régénération de glande lacrymale
KR102466794B1 (ko) 상처 치료 방법
CN118475604A (zh) Wnt受体特异性化合物及其相关方法
CN118176022A (zh) 肺部病症中wnt信号传导的调节

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20251222

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR